Trial reportJournal of endocrinological investigation2025
Efficacy and safety of beinaglutide with continuous subcutaneous infusion in newly diagnosed patients with type 2 diabetes: a randomized, control, open-labeled clinical trial.
Trial report in Journal of endocrinological investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeTo explore the efficacy and safety of continuous subcutaneous glucagon-like peptide-1 receptor agonist infusion (CSGI) combined with continuous subcutaneous insulin infusion (CSII) on body weight, glycemic control and β-cell function in newly diagnosed type 2 diabetes (T2D) patients.
methodsFrom May 2018 to November 2021, 30 newly diagnosed T2D patients at Nanjing First Hospital were recruited then randomized 1:1 to receive either CSGI add-on to CSII or CSII for 4 weeks. The oral glucose tolerance test (OGTT) and 3-day continuous glucose monitoring (CGM) were performed at the baseline and endpoint. The primary outcome was body weight change from baseline to endpoint.
resultsAfter treatment for 4 weeks, the CSGI add-on group achieved greater weight reduction (- 8.8 ± 4.5 kg vs. 0.0 ± 1.8 kg; P < 0.001) and BMI decrease (3.0 ± 1.3 vs. 0.0 ± 0.7 kg/m²; P < 0.001) versus CSII alone, with 80% (vs. 0%) losing ≥ 5% body weight (P < 0.001). While glycemic control improved in both groups, the CSGI add-on group required lower insulin doses to maintain euglycemia and showed enhanced β-cell function (P < 0.05). No serious adverse events occurred.
conclusionsAdding CSGI to CSII therapy significantly led to significant weight loss and glycemic control in new diagnosed T2D patients. This combined approach shows promise but needs more research. TRIAL REGISTRATION NUMBER: ChiCTR1800015914, registered on 28 April, 2018.
Indexed as
Identifiers
40719951What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.